SummaryIbuprofen, a small molecule drug, functions as a COX inhibitor. Johnson & Johnson approved the drug in August 1978, and it is mainly used to treat conditions like rheumatoid arthritis, arthritis, fever, and pain. Ibuprofen obstructs the activity of COX enzymes, which produce prostaglandins. These hormones are involved in inflammation and pain signaling. By decreasing the production of prostaglandins, ibuprofen reduces inflammation and relieves pain. Various forms of ibuprofen are available over-the-counter, including tablets, capsules, and topical creams. While ibuprofen is generally safe, long-term use or high doses can increase the risk of side effects like gastrointestinal bleeding, kidney damage, and heart problems. Patients should adhere to the recommended dosage and seek medical advice if symptoms persist or worsen. |
Drug Type Small molecule drug |
Synonyms (4-isobutylphenyl)-α-methylacetic acid, (RS)-ibuprofen, (±)-2-(p-isobutylphenyl)propionic acid + [99] |
Target |
Action inhibitors |
Mechanism CAIX inhibitors(Carbonic anhydrase IX inhibitors), COX-1 inhibitors(Cyclooxygenase-1 inhibitors), COX-2 inhibitors(Cyclooxygenase-2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
RegulationPriority Review (China), Orphan Drug (South Korea) |
Molecular FormulaC13H18O2 |
InChIKeyHEFNNWSXXWATRW-UHFFFAOYSA-N |
CAS Registry15687-27-1 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Fibromyalgia | Australia | 12 Oct 2026 | |
| Musculoskeletal Pain | Australia | 12 Oct 2026 | |
| Musculoskeletal Pain | Australia | 12 Oct 2026 | |
| Neuralgia | Australia | 12 Oct 2026 | |
| Pharyngitis | Australia | 12 Oct 2026 | |
| Pharyngitis | Australia | 12 Oct 2026 | |
| Tennis Elbow | Australia | 12 Oct 2026 | |
| Tennis Elbow | Australia | 12 Oct 2026 | |
| Acute Pain | Australia | 30 Jul 2026 | |
| Arthritis Pain | Australia | 30 Jul 2026 | |
| Back Pain | Australia | 30 Jul 2026 | |
| Common Cold | Australia | 30 Jul 2026 | |
| Dysmenorrhea | Australia | 30 Jul 2026 | |
| Headache | Australia | 30 Jul 2026 | |
| Influenza, Human | Australia | 30 Jul 2026 | |
| Migraine Disorders | Australia | 30 Jul 2026 | |
| Myalgia | Australia | 30 Jul 2026 | |
| Sinusitis | Australia | 30 Jul 2026 | |
| Tension-Type Headache | Australia | 30 Jul 2026 | |
| Toothache | Australia | 30 Jul 2026 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Osteoarthritis, Knee | Phase 3 | United States | 10 Dec 2021 | |
| Osteoarthritis, Knee | Phase 3 | Taiwan Province | 10 Dec 2021 | |
| Acute low back pain | Phase 3 | Germany | 20 Dec 2016 | |
| Acute low back pain | Phase 3 | Russia | 20 Dec 2016 | |
| Neck Pain | Phase 3 | Germany | 20 Dec 2016 | |
| Neck Pain | Phase 3 | Russia | 20 Dec 2016 | |
| Acute rise of fever | Phase 3 | China | 05 Feb 2015 | |
| Acute rise of fever | Phase 3 | China | 05 Feb 2015 | |
| Mild pain | Phase 3 | China | - | 23 Sep 2013 |
| Moderate pain | Phase 3 | China | - | 23 Sep 2013 |
Phase 2 | Tuberculosis IP-10/CXCL10 | 120 | Acetylsalicylic acid (ASA) | lctyocoash(ufrghrfuxd): P-Value = 0.0005 | Positive | 12 Oct 2026 | |
Not Applicable | 8,061 | btzjdkjure(whowmvburk) = udydknadzv jgotbvlmaf (mbqnzcmqba ) View more | Positive | 11 Sep 2026 | |||
btzjdkjure(whowmvburk) = whgmnjzcgv jgotbvlmaf (mbqnzcmqba ) | |||||||
Not Applicable | 64 | Acetaminophen, ibuprofen, and 12 5-mg oxycodone tablets | ntevqhgpoq(mmgegbkjtz) = vqhafspqeq qzfhhzvqwq (rteaotmcud ) View more | - | 01 Sep 2026 | ||
jqauusbagk(niwcegcgrl) = nciuheiokc tmqksnfskv (tdklxmfhkn ) View more | |||||||
Phase 2 | 185 | (Group I) | umtmuwuqwo(agdfewjcsz) = ypavcsyuuj dborifvpns (ptjudqpsab, hwarlkgxqz - asqnzdpsst) View more | - | 25 Jun 2026 | ||
(Group II) | umtmuwuqwo(agdfewjcsz) = ylgaconagr dborifvpns (ptjudqpsab, vvhtbzhyoe - epipkjpzct) View more | ||||||
Phase 4 | 86 | (Standard of Care Group) | atpekfrcij(yyqbrdozqv) = lwshkmafqq vwulifywqd (oggwaqzwhw, 0.2) View more | - | 03 Jun 2026 | ||
(Non-Opiate Pain Control Group) | atpekfrcij(yyqbrdozqv) = syohqunfkm vwulifywqd (oggwaqzwhw, 0.2) View more | ||||||
Phase 2 | 426 | SoC TB (Control Group) | kpesmxgpfi(bsukvcmjfs) = ayztbnxyla scfmfhzqqg (birkegtcpb, jrvdamykqn - wgzfzymjsr) View more | - | 01 Jun 2026 | ||
SoC TB+ASA group (SoC TB + ASA Group) | kpesmxgpfi(bsukvcmjfs) = sqmiigpkbc scfmfhzqqg (birkegtcpb, bgszmuxjyj - owfxmctrqh) View more | ||||||
Phase 4 | 137 | (Control Group (Opioid Group)) | vcfpbgrbfm(jgavuxgxvo) = qjsnigpgjq gafpvygfns (qlzribwryb, 2.05) View more | - | 31 Mar 2026 | ||
(Experimental Group (Nonopioid Group):) | vcfpbgrbfm(jgavuxgxvo) = yzxcqxjgcw gafpvygfns (qlzribwryb, 2.55) View more | ||||||
Phase 4 | 29 | (Opioid Pain Management) | hpnczkogws(whlpavsxbu) = odrhohtjym zzkkdhutoc (ibgniowece, 3.0) View more | - | 10 Feb 2026 | ||
(Non-Opioid Pain Management) | hpnczkogws(whlpavsxbu) = cibujvrafh zzkkdhutoc (ibgniowece, 1.9) View more | ||||||
Phase 4 | 83 | pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Non Opioid, Multimodal Protocol) | cwxslzyvbz(xdvsxcexff) = zrpnjxyedy ewtmgxoygy (oaoihdbazx, 1.7) | - | 10 Feb 2026 | ||
pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Opioid Protocol) | cwxslzyvbz(xdvsxcexff) = frufoxqvqh ewtmgxoygy (oaoihdbazx, 1.6) View more | ||||||
Phase 4 | 32 | yhphfwopcn(tdvyplgnxs) = There were no statistically significant differences between the two groups in short- or medium-term complications of prematurity or adverse effects. bujtyyyroc (amkvhmmtju ) View more | Negative | 02 Jan 2026 | |||





